Loading
A phase 1/2 trial of Vactosertib in osteosarcoma, run by MedPacto, Inc., now recruiting.
Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma is a phase 1/2 interventional study registered as NCT05588648 by MedPacto, Inc., with 48 participants planned, started 2023-05-01 and due to reach its primary completion in 2025-09. Interventions recorded: Vactosertib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/